MedTrace Logo

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

NCT06793709 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-02-27

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the safety of Tasfygo.

Conditions

  • Biliary Tract Cancer

Interventions

OTHER

No Intervention

This is a non-interventional study.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-10
Primary Completion
2032-11-20
Completion
2032-11-20

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06793709 on ClinicalTrials.gov